Acknowledgement
본 연구는 금오공과대학교 학술연구비에 의하여 연구된 논문 임 (2021).
References
- Roden DM, "Cellular basis of drug-induced torsades de pointes", Br. J. Pharmacol., 2008;154:1502-1507, doi:10.1038/bjp.2008.238.
- Shah RR, "Drugs, QTc interval prolongation and final ICH E14 guideline: An important milestone with challenges ahead", Drug Saf., 2005;28(11):1009-1028, doi:10.2165/00002018- 200528110-00003.
- Cavero I, Crumb W, "ICH S7B draft guideline on the nonclinical strategy for testing delayed cardiac repolarisation risk of drugs: A critical analysis", Expert Opin. Drug Saf., 2005;4(3):509-530, doi:10.1517/14740338.4.3.509.
- Strauss DG, et al., "Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting", Ther. Innov. Regul. Sci., 2019;53(4):519-525, doi: 10.1177/2168479018795117.
- Colatsky T, et al., "The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress", J. Pharmacol. Toxicol. Methods, 2016;81:15-20, doi:10.1016/j.vascn.2016.06.002.
- Dutta S, et al., "Optimization of an in silico cardiac cell model for proarrhythmia risk assessment", Front. Physiol., 2017;8:1-15, doi:10.3389/fphys.2017.00616.
- O'Hara T, Virag L, Varro A, Rudy Y, "Simulation of the undiseased human cardiac ventricular action potential: Model formulation and experimental validation", PLoS Comput. Biol., 2011;7(5), doi:10.1371/journal.pcbi.1002061.
- Li Z, et al., "Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA Initiative", Clin. Pharmacol. Ther., 2019:105(2):466-475, doi: 10.1002/cpt.1184.
- Llopis-Lorente J, Gomis-Tena J, Cano J, Romero L, Saiz J, Trenor B, "InSilico Classifiers for the Assessment of Drug Proarrhythmicity", J. Chem. Inf. Model., 2020;60(10):5172-5187, doi:10.1021/acs.jcim.0c00201.
- Lancaster MC, Sobie EA, "Improved Prediction of Drug-Induced Torsades de Pointes Through Simulations of Dynamics and Machine Learning Algorithms", Clin. Pharmacol. Ther., 2016;100(4):371-379, doi:10.1002/cpt.367.
- Ismail WN, Hassan MM, Alsalamah HA, Fortino G, "CNNbased health model for regular health factors analysis in internetof-medical things environment", IEEE Access, 2020;8:52541-52549, doi:10.1109/ACCESS.2020.2980938.
- Chang KC, et al., "Uncertainty quantification reveals the importance of data variability and experimental design considerations for in silico proarrhythmia risk assessment", Front. Physiol., 2017;8:1-17, doi:10.3389/fphys.2017.00917.
- Hwang M, Lim C-H, Leem CH, Shim EB, "In silico models for evaluating proarrhythmic risk of drugs", APL Bioeng., 2020;4(2):021502, doi:10.1063/1.5132618.
- Simundic AM, "Measures of Diagnostic Accuracy: Basic Definitions", Ejifcc, 2009:19(4);203-211.
- Li Z, et al., "General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA In Silico Strategy", Clin. Pharmacol. Ther., 2020;107(1):102-111, doi:10.1002/cpt.1647.